Latest Cadence Pharmaceuticals Inc. Stories
SAN DIEGO, Aug. 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences during the month of August: Ted Schroeder, President & CEO, will present the corporate overview at the Canaccord Genuity Growth Conference at the...
SAN DIEGO, July 28, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV® (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg. Cadence's announcement follows the issuance of a news release by a major manufacturer of over-the-counter (OTC) acetaminophen products announcing its plans to lower the recommended maximum...
SAN DIEGO, July 27, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its second quarter ended June 30, 2011 financial results on Wednesday, August 3, 2011. Cadence management will host a conference call and live webcast to discuss the financial results on Wednesday, August 3, 2011 at 1:30...
SAN DIEGO, June 7, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that OFIRMEV® (acetaminophen) injection has been added to the U.S. Department of Defense's Joint Deployment Formulary (JDF), the core list of pharmaceutical products required for theater-level care of deployed forces. The U.S. Food and Drug Administration (FDA) approved OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with...
SAN DIEGO, June 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company's President and CEO Ted Schroeder will present the company's corporate overview on Thursday, June 9, 2011 at 1:30pm Eastern Time (10:30am Pacific Time) during the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt...
SAN DIEGO, May 5, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2011. During the first quarter of 2011, Cadence commercially launched OFIRMEV(TM) (acetaminophen) injection, the first and only intravenous formulation of acetaminophen to be approved in...
SAN DIEGO, April 28, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2011 financial results on Thursday, May 5, 2011. Cadence management will host a conference call and live webcast to discuss the financial results on Thursday, May 5, 2011 at 5:30 am...
SAN DIEGO, April 26, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present a corporate overview at the following investment conferences during the month of May: Deutsche Bank's 36th Annual Health Care Conference at the InterContinental Hotel in...
SAN DIEGO, March 3, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the fourth quarter and year ended December 31, 2010. During the fourth quarter of 2010, Cadence received marketing approval for OFIRMEV(TM) (acetaminophen) injection from the U.S. Food and Drug Administration (FDA)....
SAN DIEGO, March 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, March 9, 2011 at 8:00am Eastern Time (5:00am Pacific Time) during the Cowen and Company 31st Annual Health Care...
